[HTML][HTML] Increased resistance of SARS-CoV-2 variants B. 1.351 and B. 1.1. 7 to antibody neutralization
2021 - europepmc.org
The Covid-19 pandemic has ravaged the globe, and its causative agent, SARS-CoV-2,
continues to rage. Prospects of ending this pandemic rest on the development of effective …
continues to rage. Prospects of ending this pandemic rest on the development of effective …
Increased Resistance of SARS-CoV-2 Variants B. 1.351 and B. 1.1. 7 to Antibody Neutralization
D Ho, P Wang, L Liu, S Iketani, Y Luo, Y Guo, M Wang… - researchsquare.com
The Covid-19 pandemic has ravaged the globe, and its causative agent, SARS-CoV-2,
continues to rage. Prospects of ending this pandemic rest on the development of effective …
continues to rage. Prospects of ending this pandemic rest on the development of effective …
Increased Resistance of SARS-CoV-2 Variants B. 1.351 and B. 1.1. 7 to Antibody Neutralization
D Ho, P Wang, L Liu, S Iketani, Y Luo, Y Guo, M Wang… - Res. Sq., 2021 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> The Covid-19 pandemic has ravaged the
globe, and its causative agent, SARS-CoV-2, continues to rage. Prospects of ending this …
globe, and its causative agent, SARS-CoV-2, continues to rage. Prospects of ending this …
Increased Resistance of SARS-CoV-2 Variants B. 1.351 and B. 1.1. 7 to Antibody Neutralization.
D Ho, P Wang, L Liu, S Iketani, Y Luo, Y Guo… - Research …, 2021 - europepmc.org
The Covid-19 pandemic has ravaged the globe, and its causative agent, SARS-CoV-2,
continues to rage. Prospects of ending this pandemic rest on the development of effective …
continues to rage. Prospects of ending this pandemic rest on the development of effective …